REGULATION OF CD45 ENGAGEMENT BY THE B-CELL RECEPTOR CD22

被引:83
|
作者
SGROI, D
KORETZKY, GA
STAMENKOVIC, I
机构
[1] MASSACHUSETTS GEN HOSP EAST,DEPT PATHOL,BOSTON,MA 02129
[2] MASSACHUSETTS GEN HOSP EAST,CTR CANC,BOSTON,MA 02129
[3] MASSACHUSETTS GEN HOSP EAST,PATHOL RES LAB,BOSTON,MA 02129
[4] HARVARD UNIV,SCH MED,BOSTON,MA 02129
[5] UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242
[6] UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242
关键词
D O I
10.1073/pnas.92.9.4026
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The B-cell receptor CD22 binds sialic acid linked alpha-2-6 to terminal galactose residues on N-linked oligosaccharides associated with several cell-surface glycoproteins. The first of these sialoglycoproteins to be identified was the receptor-linked phosphotyrosine phosphatase CD45, which is required for antigen/CD3-induced T-cell activation. In the present work we examine the effect of interaction between the extracellular domain of CD45 and CD22 on T-cell activation. Using soluble CD22-immunoglobulin fusion proteins acid T cells expressing wild-type and chimeric CD45 forms, we show that engagement of CD45 by soluble CD22 can modulate early T-cell signals in antigen receptor/CD3-mediated stimulation. We also show that addition of sialic acid by beta-galactoside alpha-2,6-sialyltransferase to the CD22 molecule abrogates interactions between CD22 and its ligands. Together, these observations provide direct evidence for a functional role of the interaction between the extracellular domain of CD45 and a natural ligand and suggest another regulatory mechanism for CD22-mediated ligand engagement.
引用
收藏
页码:4026 / 4030
页数:5
相关论文
共 50 条
  • [41] Analysis of murine CD22 during B cell development: CD22 is expressed on B cell progenitors prior to IgM
    Stoddart, A
    Ray, RJ
    Paige, CJ
    INTERNATIONAL IMMUNOLOGY, 1997, 9 (10) : 1571 - 1579
  • [42] ROLE OF THE CD22 HUMAN B-CELL ANTIGEN IN B-CELL TRIGGERING BY ANTI-IMMUNOGLOBULIN
    PEZZUTTO, A
    RABINOVITCH, PS
    DORKEN, B
    MOLDENHAUER, G
    CLARK, EA
    JOURNAL OF IMMUNOLOGY, 1988, 140 (06): : 1791 - 1795
  • [43] The B-cell inhibitory receptor CD22 is a major factor in host resistance to Streptococcus pneumoniae infection
    Fernandes, Vitor E.
    Ercoli, Giuseppe
    Benard, Alan
    Brandl, Carolin
    Fahnenstiel, Hannah
    Mueller-Winkler, Jennifer
    Weber, Georg F.
    Denny, Paul
    Nitschke, Lars
    Andrew, Peter W.
    PLOS PATHOGENS, 2020, 16 (04)
  • [44] Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition
    Aminov, Sarah
    Giricz, Orsi
    Sica, R. Alejandro
    Polishchuk, Veronika
    Yates, Bonnie
    Wang, Hao-Wei
    Wang, Yanhua
    Sahu, Srabani
    Gordon, Shanisha
    Schinke, Carolina
    Pradhan, Kith
    Aluri, Srinivas
    Janakiram, Murali
    Barta, Stefan K.
    Agarwal, Beamon
    Goldfinger, Mendel
    Shastri, Aditi
    Matsui, William
    Steidl, Ulrich
    Brody, Joshua
    Shah, Nirali N.
    Parekh, Samir
    Verma, Amit
    BLOOD, 2022, 140 : 3480 - 3481
  • [45] Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling
    Jin, L
    McLean, PA
    Neel, BG
    Wortis, HH
    JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (09): : 1199 - 1205
  • [46] Quantification of the leukocyte common antigen (CD45) in mature B-cell malignancies
    Hendrickx, A
    Bossuyt, X
    CYTOMETRY, 2001, 46 (06): : 336 - 339
  • [47] Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
    Sullivan-Chang, Loretta
    O'Donnell, Robert T.
    Tuscano, Joseph M.
    BIODRUGS, 2013, 27 (04) : 293 - 304
  • [48] Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab
    Rossi, Edmund A.
    Goldenberg, David M.
    Michel, Rosana
    Rossi, Diane L.
    Wallace, Daniel J.
    Chang, Chien-Hsing
    BLOOD, 2013, 122 (17) : 3020 - 3029
  • [49] Regulation of B cell antigen receptor signaling by the Lyn/CD22/SHP1 pathway
    Cornall, RJ
    Goodnow, CC
    Cyster, JG
    IMMUNORECEPTOR TYROSINE-BASED INHIBITION MOTIFS, 1999, 244 : 57 - 68
  • [50] Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
    Loretta Sullivan-Chang
    Robert T. O’Donnell
    Joseph M. Tuscano
    BioDrugs, 2013, 27 : 293 - 304